Why the study?
The study was conducted to evaluate the safety and efficacy of guideline-recommended risk score-directed dual antiplatelet therapy based on the PRECISE-DAPT score after 2nd-generation DES implantation.
Does guideline-recommended risk score-directed dual antiplatelet therapy based on the PRECISE-DAPT score improve net adverse clinical events in patients after 2nd-generation drug-eluting stent implantation?
Does guideline-recommended risk score-directed dual antiplatelet therapy based on the PRECISE-DAPT score improve net adverse clinical events in patients after 2nd-generation drug-eluting stent implantation?
Using the PRECISE-DAPT score to guide dual antiplatelet therapy duration after 2nd-generation DES implantation optimizes the balance between ischemic and bleeding risks, particularly in patients with acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
GD-DAPT does not reduce NACE overall after 2nd-generation DES; extends evidence for ischemic event reduction versus shorter DAPT.
BACKGROUND: Evaluate the safety and efficacy of guideline-recommended risk score-directed dual antiplatelet therapy (GD-DAPT) based on THE PRECISE-DAPT score after 2nd-generation drug-eluting stent (DES) implantation. METHODS AND RESULTS: We analyzed 5,131 patients pooled from 4 clinical trials. Patients were divided into 3 groups according to current recommendations on the duration of DAPT and their actual DAPT duration: GD-DAPT (n=2,183), shorter DAPT (n=1,540), longer DAPT (n=1,408). The primary endpoint was the rate of net adverse clinical events (NACE) during the first 12 months. The secondary endpoints were ischemic or bleeding events. Overall, GD-DAPT did not affect NACE (1.2% vs. 1.2% for shorter DAPT and 1.7% for longer DAPT) or bleeding events (0.6% vs. 0.5% and 0.9%), and there were fewer ischemic events (2.8% vs. 4.4% and 4.0%, P=0.03) than with shorter DAPT. Especially in acute coronary syndrome (ACS) patients, GD-DAPT had fewer NACE (1.5% vs. 1.4% and 4.2%; P=0.006) and bleeding events (0.8% vs. 0.5% and 2.8%; P=0.001) than longer DAPT as well as fewer ischemic events (2.8% vs. 4.4% and 4.7%; P=0.03) than shorter DAPT. CONCLUSIONS: GD-DAPT did not affect NACE or bleeding events and reduced the number of ischemic events at 12 months compared with shorter DAPT. For ACS, GD-DAPT was associated with favorable outcomes compared with non-GD-DAPT. Therefore, GD-DAPT may optimize efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: